Cooperative Agreement U13NS077720

The National Institute of Neurological Disorders and Stroke (NINDS) awarded Aquinnah Pharmaceuticals, Inc. a $1,499,212 Project Grant (CFDA 93.853) to develop a novel oral brain-penetrant therapeutic for Amyotrophic Lateral Sclerosis (ALS). The funding will support manufacturing, IND-enabling studies, and a PIND meeting with the FDA for this innovative new clinical drug candidate designed to slow and potentially reverse ALS disease progression. The proposed therapeutic targets the key...

This Project Grant award, valued at $558,182 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The research team at The Washington University will develop advanced proteomic assays to analyze neurofilament isoforms and...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $427,625.00 to The Washington University in St. Louis, Missouri to develop novel cellular models for studying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The funded research will employ direct neuronal conversion techniques to generate...

The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...

This $2,147,016 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of a blood-based biomarker test for amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. The awardee, Neurodex Inc., aims to validate analytical methods for their EXOSORT technology, which isolates neuron-derived extracellular...

This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) will provide $6,133,297 to Mayo Clinic Jacksonville to establish an Expanded Access Program (EAP) that offers the experimental drug ibudilast to 200 amyotrophic lateral sclerosis (ALS) patients over 6 months. The project will develop a network of ALS physicians to manage the EAP, which will feature self-activation, streamlined workflows, home-based evaluations,...

The U.S. Defense Health Agency awarded a $1,979,313 Project Grant to Sachi Bioworks, Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the development of a novel, brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). Sachi Bioworks, a self-certified small disadvantaged business located in Erie, Colorado, specializes in advanced biotechnology research and development with a focus on innovative...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, is focused on developing a novel phosphorodiamidate morpholino oligonucleotide (PMO) RNA therapeutic to treat Alzheimer's disease (AD). The $238,500 award, running from December 1, 2024 to November 30, 2026, aims to create a highly effective PMO therapeutic that can selectively target the amyloid precursor protein (APP) to prevent the buildup of amyloid...

The Defense Health Agency awarded a $458,516 Project Grant to Mayo Clinic Jacksonville to support research titled "NOVEL THERAPEUTICS TARGETING STRESS GRANULES FOR C9ORF72-MEDIATED ALS." The grant period runs from February 1, 2021 through June 30, 2022. The grant supports research into novel therapeutics targeting stress granules for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9orf72 gene. This work falls under the Military Medical Research and...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $3,357,206 to Allyx Therapeutics Inc. to conduct clinical evaluation of the drug BMS-984923 for the treatment of Alzheimer's disease (AD). The project aims to develop a novel disease-modifying compound that targets the underlying mechanism of synapse loss, a key driver of cognitive decline in AD. Preliminary studies have demonstrated the drug's efficacy in preclinical mouse models, where...